Biotech companies often fail to replicate the promising results from academic studies, presenting a significant hurdle to translating lab discoveries into medicines. The Wall Street Journal covered the problem in a story Friday, citing biotech giant Amgen's ($AMGN) inability to replicate Boston scientists' study involving a potential protein target for cancer drugs. "I was disappointed but not surprised," Amgen's Glenn Begley told the WSJ. Article (sub. req.)